Merus N.V.
General ticker "MRUS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.9B (TTM average)
Merus N.V. follows the US Stock Market performance with the rate: 52.7%.
Estimated limits based on current volatility of 0.1%: low 95.98$, high 96.18$
Factors to consider:
- Total employees count: 260 (+51.2%) as of 2024
- Top business risk factors: Improper conduct, Geopolitical risks, Environmental liabilities, Strategic risks and growth management, Market risk
- Current price 76.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [23.68$, 54.61$]
- 2025-12-31 to 2026-12-31 estimated range: [16.08$, 38.99$]
Financial Metrics affecting the MRUS estimates:
- Negative: with PPE of -15.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.85 <= 0.33
- Positive: Shareholder equity ratio, % of 82.78 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -8.11
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Inventory ratio change, % of -9.01 <= -0.75
Short-term MRUS quotes
Long-term MRUS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $38.84MM | $39.81MM | $36.13MM |
| Operating Expenses | $188.30MM | $181.61MM | $308.20MM |
| Operating Income | $-149.46MM | $-141.80MM | $-272.07MM |
| Non-Operating Income | $27.83MM | $4.35MM | $64.89MM |
| R&D Expense | $148.23MM | $132.75MM | $225.37MM |
| Income(Loss) | $-121.63MM | $-137.45MM | $-207.18MM |
| Taxes | $0.90MM | $2.89MM | $8.15MM |
| Profit(Loss)* | $-131.19MM | $-154.94MM | $-215.33MM |
| Stockholders Equity | $247.06MM | $356.34MM | $647.93MM |
| Assets | $376.54MM | $455.49MM | $782.69MM |
| Operating Cash Flow | $-149.90MM | $-142.21MM | $-185.84MM |
| Capital expenditure | $7.64MM | $3.98MM | $1.67MM |
| Investing Cash Flow | $2.80MM | $-27.02MM | $-220.22MM |
| Financing Cash Flow | $58.74MM | $230.09MM | $494.01MM |
| Earnings Per Share** | $-2.92 | $-3.00 | $-3.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.